MERCK & COMPANY; INC. (NYSE: MRK)

View Portfolio
Back to Investopedia
Back to Investopedia




$37.05 0.46 (1.26%)
Real-time 12:00:00 AM ET
 Turn On
KEY STATS
52-Week High Price
41.56
52-Week Low Price
20.05
Avg Volume (3 Mo.)
18.00 M
Market Cap
113.83 B
P/E Ratio (TTM)
19.2
Diluted EPS (TTM)
3.27
Shares
3099.07 M
Dividend Rate ($) / (%)
1.52/4.10
91%
9%
You need to upgrade your Flash Player to view the graph.
View by Date Range:
12 Mo. Price Change : 23% - MRK has underperformed the S&P 500 by 3%
SIMILAR COMPANIES
NameCurrent Price - Today's ChangeMarket Cap
JOHNSON & JOHNSON (JNJ) $63.44 -  $1.07(1.72%)172.83 B
PFIZER INC (PFE) $18.05 -  $0.21(1.18%)144.93 B
NOVARTIS AG ADS (NVS) $53.72 -  $0.64(1.21%)120.96 B
GLAXOSMITHKLINE PLC (GSK) $38.70 -  $0.58(1.52%)107.74 B
SANOFI-AVENTIS ADS (SNY) $36.60 -  $0.69(1.92%)93.43 B
ABBOTT LABORATORIES (ABT) $53.91 -  $0.56(1.04%)83.48 B
ASTRAZENECA PLC (AZN) $44.50 -  $1.37(3.18%)62.34 B
AMGEN INC (AMGN) $57.95 -  $0.49(0.85%)58.38 B
TEVA PHARMACEUTICAL LTD (TEVA) $57.57 -  $0.65(1.14%)51.77 B
BRISTOL-MYERS SQUIBB CO (BMY) $24.39 -  $0.43(1.79%)47.48 B
As of February 09, 2010 at 12:40 PM ET
STOCK ANALYSIS
Stock Analysis
Dogs Of The Dow For 2010 (T, VZ, DD, KFT, MRK, MCD)
Will this well-heeled strategy pay off in the next 12 months?
Stock Analysis
2009's "Dogs of the Dow" (BAC, GE, PFE, DD, AA, T, VZ, MRK, JPM, KFT)
Was there any bite to the Dogs of the Dow strategy last year?
Stock Analysis
A Review Of The Drug Makers Of 2009 (PFE, MRK, BMY)
Corporate deal-making was the name of the big pharma game in 2009 and will likely continue into the new year.
Stock Analysis
AmerisourceBergen Profitably Pushing Drugs (ABC, MCK, CVS)
AmerisourceBergen should continue to grows its top line modestly and generate substantial cash flow for shareholders.
Stock Analysis
Bears Are Still Growling On Wall Street (C, ETFC, GE, PFE, MRK)
Not every investor is optimistic about the economy, and this attitude shows in an examination of the latest data on...
View All Stock Analysis
MRK RELATED HEADLINES
arrow
Merck (MRK) Gets 4 Star Buy Rating From S&P With 3.9% Dividend Yield
Merck (NYSE: MRK) ended the last trading session at $36.73. So far the stock has hit a 52-week low of $20.05 and 52-week high of $41.56. Merck stock has been showing support around 35.28 and resistance in the 37.80 range. Technical indicators for the stock are Bearish and S&P gives MRK a positive 4 STAR (out of 5) buy rating. MRK appears on the Investors Observer Volume Leaders list. For a hedged play on this stock, look at an Apr '10 36 covered call for a net debit in the $34.45 area. That is also the break even stock price for this trade. This covered call has a 68 day duration, provides 6.21% do...
At Market Intelligence Center 2/9/2010
arrow
A Win For Crestor, AstraZeneca
The Food and Drug Administration is approving the statin drug Crestor to prevent heart attacks, strokes, and heart procedures in patients with normal levels of bad cholesterol but high levels of c-reactive protein, a marker for heart inflammation, according to a Q&A on the FDA Web site. The new approval could result in millions more ...
Forbes.com 2/8/2010
arrow
Time To Sue Toyota!
Carmaker hits the ropes, and class-action heavies jump into the ring.
Forbes.com 2/4/2010
arrow
Where's The Sunshine For Unemployables?
A rise in structural unemployment, coupled with the urge to pay down debt, is not encouraging, but I'm still inclined to be bullish.
Forbes.com 2/4/2010
arrow
No Sunshine For The Unemployables
A rise in structural unemployment, coupled with the urge to pay down debt, is not encouraging, but I'm still inclined to be bullish.
Forbes.com 2/4/2010
arrow
Ten Questions About High Cholesterol
The biggest heart risk factor still mystifies top scientists. Here's what you need to know.
Forbes.com 2/3/2010
View All Headlines
Stock Simulator- Free Account
Chart Advisor- Free Report
Sponsored Links
COLOSIM1